February 23, 2023 12:58 PM ESTUpdated February 24, 08:51 AM
Pharma

CMS not ready to re­con­sid­er its block on cov­er­ing new Alzheimer's drugs

Zachary Brennan

Senior Editor

The Cen­ters for Medicare and Med­ic­aid Ser­vices won’t yet re­con­sid­er a de­ci­sion that FDA-ap­proved, amy­loid-tar­get­ing mon­o­clon­al an­ti­bod­ies for Alzheimer’s dis­ease shouldn’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times